礼来(LLY.US)FRα ADC启动III期临床研究

智通财经
Oct 10

智通财经APP获悉,10月9日,全球临床试验收录网站显示,礼来(LLY.US)启动了FRα ADC药物LY4170156的首个III期临床试验(FRAmework-01)。LY4170156是Mablink Bioscience(已被礼来收购)开发的一款FRα ADC药物,其有效载荷为拓扑异构酶I抑制剂依沙替康,DAR值为8。

据医药魔方NextPharma数据库统计,目前全球共27款在研FRα ADC药物,其中11款处于临床阶段。除了已经上市的索米妥昔单抗外,Rinatabart sesutecan(Genmab)、BAT8006(百奥泰)和LY4170156是进展最快的3款药物,均已启动III期临床试验。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10